Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vito Lorusso

Showing results (101-110 of 218) with videos related to

Pageof 22
Sort By:
Tumori|April 27, 2005
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesotheliomaLuigi Portalone, Antonio Antilli, Francesco Nunziati, et al.
Journal of Clinical Medicine|August 4, 2015
Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational StudyAmit Bahl, Herbert Hoefeler, Ignacio Duran, et al.
Springerplus|July 22, 2014
Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational studyDiana Lüftner, Vito Lorusso, Ignacio Duran, et al.
AJR. American Journal of Roentgenology|July 23, 2004
Radiofrequency ablation of 40 lung neoplasms: preliminary resultsCosmo Gadaleta, Vittorio Mattioli, Giuseppe Colucci, et al.
Journal of Translational Medicine|December 24, 2003
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialMichele Guida, Alessandra Ravaioli, Vanna Chiarion Sileni, et al.
Scientific Reports|October 30, 2020
Hounsfield unit attenuation value can differentiate pyonephrosis from hydronephrosis and predict septic complications in patients with obstructive uropathyLuca Boeri, Irene Fulgheri, Franco Palmisano, et al.
The Breast Journal|November 6, 2009
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancerGiulio Metro, Diana Giannarelli, Donatello Gemma, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 16, 2021
Advancement study of CancerMath model as prognostic tools for predicting Sentinel lymph node metastasis in clinically negative T1 breast cancer patientsRaffaella Massafra, Domenico Pomarico, Annarita Fanizzi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?Diego Cortinovis, Paolo Bidoli, Daniela Cullurà, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 13, 2023
Receptive music therapy versus group music therapy with breast cancer patients hospitalized for surgeryFulvia Lagattolla, Barbara Zanchi, Milella Pietro, et al.
Pageof 22

Showing results (101-110 of 218) with videos related to

Sort By:
Pageof 22
Tumori|April 27, 2005
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesotheliomaLuigi Portalone, Antonio Antilli, Francesco Nunziati, et al.
Journal of Clinical Medicine|August 4, 2015
Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational StudyAmit Bahl, Herbert Hoefeler, Ignacio Duran, et al.
Springerplus|July 22, 2014
Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational studyDiana Lüftner, Vito Lorusso, Ignacio Duran, et al.
AJR. American Journal of Roentgenology|July 23, 2004
Radiofrequency ablation of 40 lung neoplasms: preliminary resultsCosmo Gadaleta, Vittorio Mattioli, Giuseppe Colucci, et al.
Journal of Translational Medicine|December 24, 2003
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialMichele Guida, Alessandra Ravaioli, Vanna Chiarion Sileni, et al.
Scientific Reports|October 30, 2020
Hounsfield unit attenuation value can differentiate pyonephrosis from hydronephrosis and predict septic complications in patients with obstructive uropathyLuca Boeri, Irene Fulgheri, Franco Palmisano, et al.
The Breast Journal|November 6, 2009
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancerGiulio Metro, Diana Giannarelli, Donatello Gemma, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 16, 2021
Advancement study of CancerMath model as prognostic tools for predicting Sentinel lymph node metastasis in clinically negative T1 breast cancer patientsRaffaella Massafra, Domenico Pomarico, Annarita Fanizzi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?Diego Cortinovis, Paolo Bidoli, Daniela Cullurà, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 13, 2023
Receptive music therapy versus group music therapy with breast cancer patients hospitalized for surgeryFulvia Lagattolla, Barbara Zanchi, Milella Pietro, et al.
Pageof 22